TME Pharma N.V.
Research TME Pharma N.V. (ALTME) on Bullrun: market cap EUR 14.24M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALTME
- ExchangePA
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 14.24M
- Financial periodFY2025
- RevenueEUR 0
- Net income-EUR 3.29M
- Free cash flow-EUR 3.42M
Valuation Snapshot
latest market cap is EUR 14.24M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 3.29M | -EUR 3.42M | n/a | n/a | EUR 2.01M | EUR 2.39M | -EUR 1.58M |
| FY2024 | EUR 0 | -EUR 5.72M | -EUR 4.65M | n/a | -0.12 | EUR 3.24M | EUR 0 | EUR 1.61M |
| FY2023 | EUR 0 | -EUR 6.74M | -EUR 5.65M | n/a | -1 | EUR 2.25M | EUR 1.17M | -EUR 294.00K |
| FY2022 | EUR 0 | -EUR 15.13M | -EUR 12.16M | n/a | -9.59 | EUR 4.63M | EUR 4.09M | -EUR 1.27M |
| FY2021 | EUR 0 | -EUR 14.45M | -EUR 12.40M | n/a | -14.8 | EUR 9.46M | EUR 2.44M | EUR 4.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 14.24M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About TME Pharma N.V.
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is TME Pharma N.V.'s market cap?
TME Pharma N.V.'s market capitalization is EUR 14.24M.
What does TME Pharma N.V. do?
TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company's Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for the treatment of diabetic nephropathy.